Zydus Lifesciences gets USFDA nod to market colestipol hydrochloride tablets
The approval by the US Food and Drug Administration is for colestipol hydrochloride of 1 mg strength, the company said in a regulatory filing.
New Delhi: Zydus Lifesciences Ltd on Monday said it has received the final approval from the US health regulator to market its generic version of colestipol hydrochloride tablets, which is used to lower cholesterol. The approval by the US Food and Drug Administration is for colestipol hydrochloride of 1 mg strength, the company said in a regulatory filing.Colestipol hydrochloride tablets...
New Delhi: Zydus Lifesciences Ltd on Monday said it has received the final approval from the US health regulator to market its generic version of colestipol hydrochloride tablets, which is used to lower cholesterol. The approval by the US Food and Drug Administration is for colestipol hydrochloride of 1 mg strength, the company said in a regulatory filing.
Zydus' global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.
Read Also -Zydus gets USFDA nod for diabetes drug Dapagliflozin
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd